Android app Apple app link

Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia

By MarketWatch   |   1 year ago
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia

Unicycive Therapeutics' application for approval of oxylanthanum carbonate to treat hyperphosphatemia in kidney disease patients on dialysis has been accepted by the FDA.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.